Plain-English translation of NCT06283888 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether personalizing your blood clot-preventing medication based on your genetic makeup—specifically a gene called CYP2C19—can prevent heart problems and bleeding better than standard treatment. All participants will receive dual antiplatelet therapy (two blood thinners) right before and after a heart stent procedure. The study will compare a genotype-guided approach, where your medication is chosen based on your genes, with a conventional approach that uses standard doses for everyone.
Some people metabolize (break down) blood clot-preventing medications differently based on their genes, which can affect how well these medications work and whether they cause bleeding. This trial aims to discover whether tailoring medication selection to your individual genetic profile can prevent serious heart problems and dangerous bleeding better than the one-size-fits-all approach used today.
You likely qualify if…
You likely don't qualify if…
You will first receive standard dual blood clot-preventing medication before your stent procedure. After your procedure, you'll have a blood sample taken for genetic testing. Based on your results, you'll be randomly assigned to either the genotype-guided group (where your medication dose is tailored to your genes) or the standard treatment group. You'll take your assigned medication daily for the first 3 months, then switch to a single blood clot-preventing medication for the remaining 9 months. You'll return for follow-up visits over the course of one year to monitor for heart problems and bleeding complications.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China